iNtRON Biotechnology Inc (048530) - Total Assets
Based on the latest financial reports, iNtRON Biotechnology Inc (048530) holds total assets worth ₩78.70 Billion KRW (≈ $53.34 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check iNtRON Biotechnology Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
iNtRON Biotechnology Inc - Total Assets Trend (2012–2024)
This chart illustrates how iNtRON Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. Explore investment intensity of iNtRON Biotechnology Inc to see how much of total assets are deployed in long-term investments.
iNtRON Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
iNtRON Biotechnology Inc's total assets of ₩78.70 Billion consist of 60.5% current assets and 39.5% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 39.8% |
| Accounts Receivable | ₩912.97 Million | 1.1% |
| Inventory | ₩1.12 Billion | 1.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩1.37 Billion | 1.6% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how iNtRON Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 048530 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: iNtRON Biotechnology Inc's current assets represent 60.5% of total assets in 2024, an increase from 42.1% in 2012.
- Cash Position: Cash and equivalents constituted 39.8% of total assets in 2024, up from 15.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 33.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 1.6% of total assets.
iNtRON Biotechnology Inc Competitors by Total Assets
Key competitors of iNtRON Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
USA | $763.95 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Jiangxi Fushine Pharmaceutical Co Ltd
SHE:300497
|
China | CN¥4.48 Billion |
|
Novavax Inc
NASDAQ:NVAX
|
USA | $1.04 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
iNtRON Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.70 | 51.05 | 6.40 |
| Quick Ratio | 10.49 | 49.99 | 6.28 |
| Cash Ratio | 0.00 | 36.28 | 0.00 |
| Working Capital | ₩42.70 Billion | ₩55.93 Billion | ₩68.62 Billion |
iNtRON Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between iNtRON Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.34 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -12.4% |
| Total Assets | ₩86.37 Billion |
| Market Capitalization | $59.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values iNtRON Biotechnology Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: iNtRON Biotechnology Inc's assets decreased by 12.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual total assets of iNtRON Biotechnology Inc from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩86.37 Billion ≈ $58.53 Million |
-12.41% |
| 2023-12-31 | ₩98.61 Billion ≈ $66.83 Million |
-30.04% |
| 2022-12-31 | ₩140.96 Billion ≈ $95.53 Million |
-8.09% |
| 2021-12-31 | ₩153.37 Billion ≈ $103.93 Million |
+52.55% |
| 2020-12-31 | ₩100.54 Billion ≈ $68.13 Million |
+12.92% |
| 2019-12-31 | ₩89.03 Billion ≈ $60.34 Million |
+62.48% |
| 2018-12-31 | ₩54.80 Billion ≈ $37.13 Million |
+20.09% |
| 2017-12-31 | ₩45.63 Billion ≈ $30.92 Million |
-23.45% |
| 2016-12-31 | ₩59.61 Billion ≈ $40.39 Million |
+47.65% |
| 2015-12-31 | ₩40.37 Billion ≈ $27.36 Million |
+105.50% |
| 2012-12-31 | ₩19.64 Billion ≈ $13.31 Million |
-- |
About iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.